Oncology

Dr Debra Patt Underscores Permanent Changes Even as the OCM Ends

June 27th 2022, 7:22pm

Although the Oncology Care Model (OCM) is ending June 30, 2022, it does not mean practices can turn back the clock and revert to how they provided care prior to the OCM, explained Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology.

Pulling a Rabbit Out of the Hat

June 24th 2022, 11:46am

Health Care VC Leaders Talk Successes, Value-Based Care, and Nashville’s Rise

June 23rd 2022, 9:39pm

Why "tech-enabled" solutions make sense and how the Music City became the a health care hub.

Florida Cancer Specialists’ Walcker: Taking a “Holistic” Approach to Value-Based Care

June 23rd 2022, 4:38pm

Nathan H. Walcker, MBA, CEO of Florida Cancer Specialists & Research Institute (FCS) since August 2020, discusses the future of value-based care for the practice as the Oncology Care Model comes to an end.

Adding Drug Costs to the Clinical Support Equation

June 23rd 2022, 4:01pm

Amy Valley, PharmD, vice president of clinical strategy and technology solutions, Cardinal Health Specialty Solutions, discusses the Decision Path, a clinical support tool designed to inform oncology providers about drug costs along with clinical information, all embedded into the electronic health record workflow.

Value-Based Care Will “Continue to Evolve” Even if OCM Expires

June 23rd 2022, 3:07pm

Four experts from The US Oncology Network partnered with The American Journal of Managed Care® to present a webinar, “Beyond the OCM: How Are Commercial Payers & Employers Delivering Value-Based Cancer Care?”

Dr Debra Patt: Telemedicine’s Contribution to Cancer Care Robust and Meaningful

June 20th 2022, 4:15pm

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, discusses how enhancements to telemedicine precipitated by the COVID-19 pandemic have made lasting and meaningful changes to oncology care, including that these care improvements will persist post pandemic.

FDA Approves New Oncology Therapies Faster Than EMA, Study Finds

June 13th 2022, 8:36pm

The FDA is faster to approve new oncology therapies compared with the European Medicines Agency (EMA); but that speed may have consequences.

Survivors of Childhood Cancer More Likely to Be Undertreated for CVD Risk Factors

June 11th 2022, 2:39pm

Despite a greater risk of cardiovascular disease (CVD) due to exposure to chemotherapy and/or radiation, adult survivors of childhood cancer are undertreated for CVD risk factors compared with the general population.

Dr Ravi Parikh Offers Solutions to Barriers During Shift From Fee-for-Service to APMs

June 10th 2022, 6:46pm

Designing rational spending targets and having small sample sizes are 2 main challenges payers and partners face in the shift toward alternative payment models (APMs), said Ravi B. Parikh, MD, MPP, assistant professor of medical ethics and health policy, assistant professor of medicine, University of Pennsylvania.